Cancer Vaccines

Equity Research Initiated on Advaxis by Zacks Equity Research

Published in Vaccine Weekly, April 27th, 2011

2011 APR 27 -- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) vaccine company, has been given an investment rating by Zack's Equity Research, an investment research company, in their research evaluation of the Company.

Zacks' 18-page report includes detailed information about Advaxis' proprietary platform technology, the healthcare/immunotherapy market, industry peer comparisons and Advaxis' growth strategies along with their recommendations. For a free copy of the full research report, please email Zack's Equity Research scr@zacks.com with "ADXS" as the subject. Company Notice on Zack's Equity Research Any opinions,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2011-04-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry